Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Last: | $25.97 |
|---|---|
| Change Percent: | 12.04% |
| Open: | $25.9799 |
| Close: | $23.18 |
| High: | $25.98 |
| Low: | $25.94 |
| Volume: | 601 |
| Last Trade Date Time: | 02/18/2026 10:27:07 am |
| Market Cap: | $3,968,678,140 |
|---|---|
| Float: | 62,439,780 |
| Insiders Ownership: | N/A |
| Institutions: | 35 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.newamsterdampharma.com |
| Country: | NL |
| City: | Naarden |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
